Skip to content

Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

EBV Associated Lymphoma

Single-patient trial aiming to provide immunological consolidation following allogeneic stem cell transplantation to a young adult patient suffering from a systemic EBV-positive lymphoma of childhood.

null

Participation Requirements

  • Sex:

    FEMALE

  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

1. Capacity to provide informed consent
2. Age ≥ 18
3. Negative serum pregnancy test and use of effective contraception method.

Exclusion Criteria:

1. Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3, Campath)
2. Pregnancy
3. Any abnormal condition or laboratory result that is considered by the Principal Investigator capable of altering patient or study outcome.
4. Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronic GVHD) at time of enrolment or infusion.

Study Location

Ciusss-Emtl
Ciusss-Emtl
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Jean-Sébastien Delisle, MD, PhD

[email protected]
514-252-3400
Study Sponsored By
Ciusss de L'Est de l'Île de Montréal
Participants Required
More Information
Study ID: NCT06391814